Breaking News Instant updates and real-time market news.

AJG

Arthur J. Gallagher

$77.50

-0.135 (-0.17%)

, CSLT

Castlight Health

$2.82

0.12 (4.44%)

08:17
11/14/18
11/14
08:17
11/14/18
08:17

William Blair to hold a conference

7th Annual Benefit Technology Conference will be held in New York on November 14.

AJG

Arthur J. Gallagher

$77.50

-0.135 (-0.17%)

CSLT

Castlight Health

$2.82

0.12 (4.44%)

EHTH

eHealth

$33.97

-0.17 (-0.50%)

HIIQ

Health Insurance Innovations

$41.22

-1.01 (-2.39%)

  • 14

    Nov

  • 14

    Nov

  • 15

    Nov

  • 27

    Nov

AJG Arthur J. Gallagher
$77.50

-0.135 (-0.17%)

06/18/18
GSCO
06/18/18
INITIATION
Target $81
GSCO
Buy
Arthur J. Gallagher initiated with a Buy at Goldman Sachs
Goldman Sachs started Arthur J. Gallagher with a Buy rating and $81 price target.
06/18/18
GSCO
06/18/18
INITIATION
Target $81
GSCO
Buy
Arthur J. Gallagher initiated with a Buy at Goldman Sachs
Goldman Sachs analyst Yaron Knar initiated Arthur J. Gallagher with a Buy and $81price target telling investors he expects organic growth to remain stable in the 4% range through 2020, combined with further efficiency measures, should continue to drive margin expansion of roughly 50bps per year despite investments in the platform and talent. Knar believes Arthur J. Gallagher shares are undervalued given consistent utilization of free cash flow to supplement organic growth with acquired revenues.
08/06/18
MSCO
08/06/18
NO CHANGE
MSCO
Boeing, Tesla, Nvidia make Morgan Stanley 'key man risk' list
Morgan Stanley equity strategist Mark Savino noted that about 12% of CEO jobs among S&P 500 companies turned over in 2017, noting that this was the highest level of CEO departures since before the financial crisis. The 59 stocks of S&P 500 companies that had CEOs depart in 2017 underperformed the market by 11% over the next 12 months, or since the departure for instances that were less than 12 months ago, noted Savino. In cooperation with the firm's U.S. analysts, Savino and his team identified the companies in each sector they believe face the greatest level of "key man risk," which includes: Boeing (BA), Tesla (TSLA), ADT Inc. (ADT), Moody's (MCO), TransUnion (TRU), Arista Networks (ANET), Church & Dwight (CHD), Coca-Cola (KO), Monster Beverage (MNST), Coupa Software (COUP), Salesforce (CRM), FireEye (FEYE), MongoDB (MDB), Microsoft (MSFT), New Relic (NEWR), XPO Logistics (XPO), Hilton (HLT), Las Vegas Sands (LVS), Best Buy (BBY), Ulta (ULTA), Aflac (AFL), Athene Holding (ATH), Lincoln National (LNC), Arthur J. Gallagher (AJG), Chubb (CB), Amazon.com (AMZN), Activision Blizzard (ATVI), Facebook (FB), Alphabet (GOOGL), Apple (AAPL), Terex (TEX), Cleveland-Cliffs (CLF), Freeport McMoRan (FCX), FleetCor (FLT), Global Payments (GPN), Square (SQ), Jazz Pharmaceuticals (JAZZ), Cheesecake Factory (CAKE), Broadcom (AVGO), Nvidia (NVDA), Chegg (CHGG), DXC Technology (DXC), Medidata (MDSO), Pluralsight (PS), RealPage (RP), Shopify (SHOP) and T-Mobile (TMUS).
08/07/18
FBCO
08/07/18
INITIATION
Target $84
FBCO
Outperform
Arthur J. Gallagher initiated with an Outperform at Credit Suisse
Credit Suisse analyst Michael Zaremski started Arthur J. Gallagher with an Outperform rating and $84 price target. Between ongoing back-office expense efficiency initiatives, a strong M&A pipeline, his view that P&C pricing will remain fairly stable, an increasing talent recruitment pipeline, and upside optionality once the company amasses enough data/scale overseas to create its own higher-margin facilities, the analyst sees clear skies for low-double-digit earnings growth in the years to come.
CSLT Castlight Health
$2.82

0.12 (4.44%)

07/31/18
CHDN
07/31/18
DOWNGRADE
CHDN
Neutral
Castlight Health downgraded to Neutral from Buy at Chardan
07/31/18
CANT
07/31/18
NO CHANGE
CANT
Castlight Health loss of Walmart overshadows Q2 beat, says Cantor
Castlight Health's (CSLT) beat in Q2 was overshadowed by the loss of large client Walmart (WMT) and the initiation of a cost-restructuring program to mitigate the loss of revenue in 2019, Cantor Fitzgerald analyst Steven Halper tells investors in a research note. Despite positive discussions recently, Walmart decided not to renew and migrate to Complete, the analyst adds. With 25% upside potential to his $5 price target, the analyst maintains an Overweight rating on Castlight amid the post-earnings selloff.
08/16/18
CANT
08/16/18
NO CHANGE
CANT
Overweight
Cantor Fitzgerald backs 'positive' view of healthcare IT segment
Cantor Fitzgerald Steven Halper tells investors in a research note that he is maintaining a positive investment view of the healthcare IT segment, and believes demand for products and services in the sector will continue to drive long-term growth. Specifically, he continues to rate Cerner (CERN) and Evolent Health (EVH) Overweight, as both are "nicely" leveraged to population health, with Evolent mostly a pure play in the segment. Within managed care, Halper believes Overweight-rated UnitedHealth (UNH) remains well-positioned with its Optum segment.
10/18/18
WBLR
10/18/18
NO CHANGE
WBLR
Outperform
William Blair sees catalysts for Castlight shares after two-month selloff
William Blair analyst Jeffrey Garro points out that shares of Castlight Health (CSLT) have sold off steadily over the last two months following the announcement of Walmart's (WMT) nonrenewal in conjunction with weaker than expected bookings in the second quarter. The analyst, however, believes there is still support around the size of the market opportunity and the value generated by the company's healthcare navigation and well-being guidance platform for employers. Nonetheless, it will take better near-term execution before the company can reorient investors toward higher growth expectations and close the gap between its valuation and the peer group, Garro tells investors in a research note. He believes, though, that Castlight Health "may receive a pass" on the Walmart loss in time as more details emerge. Further, the looming general availability of Castlight Complete and achieving adjusted EBITDA profitability for the first time in Q4 can serve as near-term catalysts, Garro contends. He keeps an Outperform rating on the shares.
EHTH eHealth
$33.97

-0.17 (-0.50%)

07/27/18
CANT
07/27/18
NO CHANGE
Target $26
CANT
Overweight
eHealth price target raised to $26 from $22 at Cantor Fitzgerald
Cantor Fitzgerald analyst Steven Halper raised his price target for eHealth to $26 and reiterates an Overweight rating on the shares following the company's Q2 results. At face value, the quarter was not impressive, Halper tells investors in a research note. He notes, however, that management indicates that it used the quarter to optimize and invest in its go-to-market strategies in advance of the upcoming open enrollment period in Q4.
08/16/18
CHDN
08/16/18
INITIATION
Target $40
CHDN
Buy
eHealth initiated with a Buy at Chardan
Chardan initiated eHealth with a Buy and $40 price target.
10/08/18
CANT
10/08/18
NO CHANGE
Target $39
CANT
Overweight
eHealth price target raised to $39 from $26 at Cantor Fitzgerald
Cantor Fitzgerald analyst Steven Halper raised his price target for eHealth to $39 and reiterates an Overweight rating on the shares citing an improving growth outlook. After several years of investment, company is poised to drive stronger top line growth and expand margins, Halper tells investors in a research note. He believes eHealth's sales growth is likely to benefit from "strong" growth in Medicare, offset to some degree by declining Affordable Care Act individual and family plans. He views the stock's risk/reward trade-off as "compelling."
10/25/18
10/25/18
NO CHANGE

eHealth reports Q3 EPS (47c), consensus (36c)
Reports Q3 revenue $40.8M, consensus $35.52M.
HIIQ Health Insurance Innovations
$41.22

-1.01 (-2.39%)

09/27/18
RILY
09/27/18
NO CHANGE
Target $60
RILY
Buy
Health Insurance Innovations price target raised to $60 from $56 at B. Riley FBR
B. Riley FBR analyst Randy Binner raised his price target for Health Insurance Innovations to $60 after hosting investor meetings with management. The company's revenue opportunities "are numerous" against a backdrop of continued mainstreaming of short-term and limited-benefit health plans that it distributes, Binner tells investors in a research note. He keeps a Buy rating on the shares.
10/29/18
FANA
10/29/18
UPGRADE
Target $65
FANA
Strong Buy
Health Insurance upgraded to Strong Buy from Outperform at First Analysis
First Analysis analyst Frank Sparacino upgraded Health Insurance Innovations to Strong Buy with an unchanged price target of $65. Federal regulatory guidance and a proposed rule released last week may provide "further tailwinds" for the company as early as 2020, Sparacino tells investors in a research note. Further, the analyst sees the extension of short-term, limited duration insurance policy durations from three months to 12 months with automatic renewal up to 36 months and the zeroing out of the individual mandate tax penalty as having a positive impact on Health Insurance Innovations in the short-term. Sparacino says the recent pullback in shares of Health Insurance Innovations makes the valuation "particularly compelling."
10/30/18
CHLM
10/30/18
NO CHANGE
Target $65
CHLM
Buy
Health Insurance Innovations price target raised to $65 from $58 at Craig-Hallum
Craig-Hallum analyst George Sutton raised his price target for Health Insurance Innovations to $65 from $58, citing the outlook for a strong Q4, 2019 benefiting materially from ASC606, and legal accrual suggestive of a favorable outcome. The analyst reiterates a Buy rating on the shares.
10/30/18
LSCM
10/30/18
NO CHANGE
Target $75
LSCM
Buy
Health Insurance Innovations price target raised to $75 from $51 at Lake Street
Lake Street analyst Mark Argento raised his price target for Health Insurance Innovations to $75 from $51 and reiterates a Buy rating on the shares following last night's Q3 results. The stock in late morning trading is up 96c to $45.96. The company reported "impressive" Q3 results and increased fiscal 2018 guidance by the amount of the Q3 beat, Argento tells investors in a post-earnings research note. He believes Health Insurance Innovations has "plenty of positives to look forward to" in Q4 and 2019, noting that extended duration short-term medical plans are in high demand. The company "is set to tackle a large and expanding addressable market," says Argento.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.